Medivir: MIV-711 Obtains Rare Pediatric Disease Designation and Orphan Drug Designation - Redeye

Redeye sees the RPDD and ODD from the FDA as signs that the osteoarthritis programme MIV-711 is moving forward.

Länk till analysen i sin helhet: https://www.redeye.se/research/998623/medivir-miv-711-obtains-rare-pediatric-disease-designation-and-orphan-drug-designation?utm_source=finwire&utm_medium=RSS